Scopus Eşleşmesi Bulundu
6
Atıf
43
Cilt
195-195.e20
Sayfa
Özet
Introduction: The objective of this study is to predict the probability of prostate cancer in PI-RADS 3 lesions using machine learning methods that incorporate clinical and mpMRI parameters. Methods: The study included patients who had PI-RADS 3 lesions detected on mpMRI and underwent fusion biopsy between January 2020 and January 2024. Radiological parameters (Apparent diffusion coefficient (ADC), tumour ADC/contralateral ADC ratio, Ktrans value, periprostatic adipose tissue thickness, lesion size, prostate volume) and clinical parameters (age, body mass index, total prostate specific antigen, free PSA, PSA density, systemic inflammatory index, neutrophil-lymphocyte ratio [NLR], platelet lymphocyte ratio, lymphocyte monocyte ratio) were documented. The probability of prostate cancer prediction in PI-RADS 3 lesions was calculated using 6 different machine-learning models, with the input parameters being the aforementioned variables. Results: Of the 235 participants in the trial, 61 had malignant fusion biopsy pathology and 174 had benign pathology. Among 6 different machine learning algorithms, the random forest model had the highest accuracy (0.86±0.04; 95% CI 0.85–0.87), F1 score (0.91±0.03; 95% CI 0.91–0.92) and AUC value (0.92±0.06; 95% CI 0.88–0.90). In SHAP analysis based on random forest model, tumour ADC, tumour ADC/contralateral ADC ratio and PSA density were the 3 most successful parameters in predicting malignancy. On the other hand, systemic inflammatory index and neutrophil lymphocyte ratio showed higher accuracy in predicting malignancy than total PSA, age, free PSA/total PSA and lesion size in SHAP analysis. Conclusion: Among the machine learning models we developed, especially the random forest model can predict malignancy in PI-RADS 3 lesions and prevent unnecessary biopsy. This model can be used in clinical practice with multicentre studies including more patients.
Web of Science Eşleşmesi Bulundu
4
WoS Atıf
43
Cilt
Article
Belge Türü
Kaynak: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
· s. 195e11-195e20
Anahtar Kelimeler (WoS)
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 6.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi Bilgisi
Otomatik ISSN Eşleştirmesi
2025 yılı verileri
Urologic Oncology: Seminars and Original Investigations
Q1
SJR Quartile
0,997
SJR Skoru
93
H-Index
Kategoriler: Urology (Q1) · Oncology (Q2)
Alanlar: Medicine
Ülke: United States
· Elsevier Inc.
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir.
Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.
Anahtar Kelimeler
WoS |
Bir kelimeye tıklayıp ilgili kaynaktaki yayınları görün.
Makale Bilgileri
Dergi
Urologic Oncology: Seminars and Original Investigations
ISSN
1078-1439
Yıl
2025
/ 3. ay
Cilt / Sayı
43
Makale Türü
Özgün Makale
Hakemlik
Hakemli
Endeks
SCI-Expanded
JCR Quartile
Q2
Yayın Dili
İngilizce
Kapsam
Uluslararası
Toplam Yazar
9 kişi
Erişim Türü
Basılı+Elektronik
Alan
Sağlık Bilimleri Temel Alanı
Üroloji
YÖKSİS Yazar Kaydı
Yazar Adı
ALTINTAŞ EMRE,ŞAHİN ALİ,EROL SEYİT,ÖZER HALİL,GÜL MURAT,BATUR ALİ FURKAN,KAYNAR MEHMET,KILIÇ ÖZCAN,GÖKTAŞ SERDAR
YÖKSİS ID
8059576